CDMOs offering Formulation Development with Gene Therapy in United States
10 matching organizations
Formulation Development with Gene Therapy in United States is a frequent shortlist pattern for sponsors evaluating CDMO partners with regional footprint. This page lists organizations that map to all three dimensions so you can move from broad taxonomy browsing to a geography-aware candidate set.
Profiles emphasize fit-first discovery: review scope, regulatory posture, and provenance on each listing rather than treating this page as a single ranked recommendation.
When you need additional filters (indications, claim status, or free-text search), continue to the main search experience and layer criteria on top of this starting point.
- AGC Biologics
Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
- Altasciences
Mid-size early phase CRO/CDMO in Canada and the U.S. offering preclinical safety testing, clinical pharmacology (Phase I–II), bioanalysis, research services, and manufacturing with integrated capabilities.
- Ascendia Pharmaceutical Solutions
Specialty CDMO offering formulation development, analytical services, and cGMP manufacturing for small molecules and biologics from preclinical through Phase 1 and commercialization.
- Catalent
Leading global CDMO offering end-to-end development and manufacturing for pharma, biotech, and consumer health—spanning oral dose, biologics, cell and gene therapies, clinical supply, and specialty formulations with advanced technologies and worldwide GMP capacity.
- Charles River Cell & Gene Therapy
Integrated CDMO offering discovery through commercial manufacturing for cell and gene therapies, with expertise in viral vectors, cell therapy manufacturing, and regulatory support across North America, Europe, and Asia.
- FUJIFILM Biotechnologies
CDMO partner offering end-to-end biologics development and manufacturing from pre-clinical through commercialization, with expertise in cell culture, microbial fermentation, cell and gene therapy, and cGMP manufacturing across US and European facilities.
- National Resilience
End-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.
- Patheon (Thermo Fisher Pharma Services)
Global CDMO partner offering 360° integrated drug development solutions from early-stage R&D through clinical supply and commercial manufacturing for biologics and small molecules.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- Syngene International
Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Markdown mirror: /explore/svc_formulation_development/mod_gene_therapy/us.md